LP strategies should be considered only in patients with resectable stage III/IV larynx and hypopharynx SCC, ideally those who have a functional larynx. The choice of treatment must be discussed by a multidisciplinary team, and the patient must have an active role in making the decision. CRT and IC-RT are both approved larynx-preservation approaches. IC-RT has demonstrated high rates of LP without decreasing DFS or OS, compared with surgery. CRT has demonstrated better LP rates, as well as local control and LRC, compared with IC-RT, and it should be considered a standard of care.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group.
Front Oncol
August 2024
Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Article Synopsis
- Laryngeal preservation strategies in LA-LHSCC focus on curing the disease while keeping the larynx functional, reducing the need for total laryngectomy and its negative effects on quality of life.* -
- Various non-surgical treatments like radiotherapy and chemoradiation have been explored, but reliable predictors for treatment success are still lacking, which poses a significant clinical challenge.* -
- The PRESERVE trial aims to address this issue by analyzing past data to create a predictive classifier that combines various patient data types, ultimately improving patient selection for laryngeal preservation treatments.*
[Comparison of the efficacy of carelizumab combined with chemotherapy and chemotherapy alone in the induction therapy of locally advanced hypopharyngeal carcinoma].
Zhonghua Yi Xue Za Zhi
July 2024
Department of Radiation Oncology, Eye & ENT Hospital of Fudan University, Shanghai 200031, China.
To compare the efficacy and safety of carrelizumab combined with the modified TPF regimen (docetaxel, cisplatinand capecitabine) and TPF regimen alone in larynx preservation strategy for locally advanced resectable hypopharyngeal squamous cell carcinoma. A cohort study was conducted. Patients with locally advanced resectable hypopharyngeal carcinoma (cT3-4aN0-3bM0) who were treated at the Eye & ENT Hospital of Fudan University from January 2017 to April 2023 were enrolled in the study.
View Article and Find Full Text PDFMulticenter clinical trial on functional evaluation of transoral laser microsurgery for supraglottic laryngeal carcinomas.
Laryngorhinootologie
June 2024
Institute of Medical Informatics and Statistics, Christian-Albrechts-University Kiel, Germany.
Background: Transoral laser microsurgery (TLM) is an accepted and effective treatment strategy for supraglottic carcinomas. Data on oncologic and to a lesser extent functional outcomes have been published by mainly European specialized single institutions. TLM for supraglottic carcinomas has never been tested in a multicenter trial on its applicability as surgical standard at every hospital.
View Article and Find Full Text PDFNeoadjuvant Chemotherapy Improves Feasibility of Larynx Preservation and Prognosis in Resectable Locally Advanced Cervical Esophageal Cancer.
Ann Surg Oncol
August 2024
Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Background: The optimal strategy for cervical advanced esophageal cancer remains controversial in terms of oncologic outcome as well as vocal and swallowing function. Recently, in East Asian countries, neoadjuvant chemotherapy (NAC) has been a standard strategy for advanced esophageal cancer.
Methods: This study included 37 patients who underwent NAC, and 33 patients who underwent definitive chemoradiation therapy (dCRT) as larynx-preserving treatment for locally advanced cervical esophageal cancer from 2016 to 2021.
Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Larynx: A Scoping Review of Treatment Guidelines Worldwide.
Cancers (Basel)
September 2023
Group of Epidemiology and Statistics on Cancer, A.C.Camargo Cancer Center, Rua Tagua, 440, Liberdade, Sao Paulo CEP 01508-020, Brazil.
Head and neck cancer (HNC) treatments have been based on single or multimodal therapies with surgery, radiotherapy (RT), chemotherapy, and immunotherapy. However, treatment recommendations among countries may differ due to technological/human resources and usual local practices. This scoping review aims to identify, compare, and map the clinical practice guidelines (CPGs) for treating squamous cell carcinoma (SCC) of the oral cavity, oropharynx, and larynx worldwide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!